Recurrent miscarriage (RM), also known as recurrent pregnancy loss, is a distressing condition affecting around 1% of couples trying to conceive It can be very frustrating for both clinicians and patients as, despite intensive workup, no clear underlying pathology is forthcoming in at least 50% of couples. This leads to despair for patients and leaves clinicians at a loss for how to help. Desperation in both camps can promote the uptake of investigations and interventions of unproven benefit. The pathophysiology underpinning RM is incredibly diverse, involving areas such as haematology, endocrinology, immunology and genetics.
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DEFINITION OF RECURRENT MISCARRIAGE
Recurrent miscarriage (RM) affects around 1% of couples in at least 50% of whom, no obvious pathology can be identified. [1] [2] [3] [4] [5] There is a lack of consensus regarding the number of miscarriages required for defining recurrent miscarriage. If the threshold number of miscarriages required for making the diagnosis of RM is set too low, many women who have an otherwise good prognosis would be subjected to unnecessary investigations, whereas setting it too high risks avoidable pregnancy losses in patients with rectifiable pathology. This also has implications for research since inclusion of large numbers of low-risk women with inherently good prognosis would make it difficult to discern any potential benefits of a given intervention for those with underlying pathology. Setting the threshold depends on the background risk for miscarriage, and as discussed later, this risk is closely correlated with female age. Another consideration is whether biochemical or only clinically recognised pregnancies are included since the background risk of losing three clinical pregnancies is low compared to losing three biochemical pregnancies (0.3% vs 22%).
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The UK Royal College of Obstetricians and Gynaecologists (RCOG) define RM as 'the loss of three or more consecutive pregnancies'. 5 Because the RCOG considers pregnancy to extend from conception to 24 weeks of gestation, their definition includes biochemical pregnancies. The German, Austrian and Swiss Societies of Gynecology and Obstetrics (DGGG/OEGGG/SGGG) also consider RM as ≥3 consecutive losses. 7 The American Society for
Reproductive Medicine (ASRM), on the other hand, defines RM as 'two or more failed clinical pregnancies' (pregnancy in this case requiring ultrasound or histological confirmation) thereby excluding biochemical pregnancies but requiring only two losses. 8 This rationale is supported by a large study involving over 1000 women, which found that the likelihood of detecting an abnormality after two losses was similar to that after three or four or more losses.
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FEMALE AGE AND EMBRYONIC ANEUPLOIDY
Spontaneous miscarriage occurs in 10-15% of clinically recognised pregnancies, 6 ,9 the major underlying cause being DOI: 10.1111/ajo.12920
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Hayden Anthony Homer 1,2,3 embryonic aneuploidy. Since meiotic chromosome segregation errors in oocytes account for the majority of embryonic aneuploidies and increase with age, 10 the risk of having a miscarriage is strongly influenced by female age (Table 1) . 9 Consequently, the background risk of having three miscarriages for women <25 years is around 0.13% but 100 times more likely (~13%) if over 40.
6 Given the impact of female age on embryonic aneuploidy, 10 the rate-limiting risk factor for miscarriage in older women is largely untreatable.
Around 40% of miscarriages in RM patients are chromosomally abnormal, 11 highlighting the importance of embryonic aneuploidy in this population. Hence, most cases that are unexplained from a parental perspective can in fact be explained by embryonic chromosomal abnormalities. 12 Collectively, combined parental and embryonic factors provide an explanation in >90% of RM patients. 12 However, it should be noted that embryonic aneuploidy does not negate the possibility of co-existing pathology in the couple, which occurs in around a quarter of cases.
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Karyotyping of subsequent miscarriages using whole genome approaches is therefore informative. Significantly, the likelihood of there being a parental cause is heavily influenced by whether embryonic aneuploidy is present -85% of patients with euploid miscarriage tissue were found to have an abnormality following RM workup in one study. 12 Given the contribution of embryonic aneuploidy, it might be expected that screening out aneuploid embryos using in vitro that evaluated polar body PGT-A for advanced maternal age excluded RM patients but found a reduction in miscarriage rates in the PGT-A arm. 15 On the other hand, another RCT of PGT-A, this time in young good-prognosis patients and involving the much more commonly used blastocyst biopsy approach, did not report a significant reduction in miscarriage rates. 16 For the present, and consistent with a recent ASRM evaluation, 17 there is a lack of robust evidence that PGT-A in patients without known structural chromosomal abnormalities increases the chances of live births or reduces the numbers of miscarriages en route to successful livebirth in the RM population.
ANTIPHOSPHOLIPID SYNDROME (APS)
Antiphospholipid syndrome is found in 5-20% of women with RM ( 
PARENTAL STRUCTURAL CHROMOSOMAL ABNORMALITIES
Structural chromosomal abnormalities, most commonly (~85%) balanced translocations (reciprocal translocations (~60%) and Robertsonian translocations (~40%)) are found in 2-5% of RM couples (Table 2 ) compared with 0.7% of the general population. 2, 12, 23, 24 Parental karyotyping is recommended by the ASRM and the DGGG/OEGGG/SGGG. 7, 8 The RCOG proposed selective karyotyping depending on whether an unbalanced arrangement is found in the products of conception.
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Patients with chromosomal abnormalities should be referred for genetic counselling. 5, 8 Although embryos with unbalanced chromosomal arrangements can theoretically be screened out,
PGT is not routinely advised since the likelihood of a pregnancy with an unbalanced karyotype surviving into the second trimester is low (0.8% in one study 23 ) and overall livebirth rates have not been shown to be higher with IVF/PGT compared with natural conception. [25] [26] [27] However, it remains possible that PGT in couples with structural chromosomal defects might reduce the number of miscarriages experienced prior to a successful live birth, 27 but this requires further evaluation.
UTERINE STRUCTURAL ABNORMALITIES
Congenital (septate, bicornuate, unicornuate, didelphys and arcuate defects) and acquired (fibroids, polyps and adhesions) uterine defects are frequently identified in RM patients (Table 2) . 2 In one study of over 900 RM patients, uterine anomalies were identified in 19.5% of patients with 6.2% and 13.3% being congenital and acquired, respectively. 28 An assessment of uterine anatomy is therefore recommended for patients with RM.
ultrasonography with or without saline infusion (sonohysterography) usually constitutes first-line investigations. The Thessaloniki ESHRE/ESGE consensus group recommended 3-D ultrasonography for investigating uterine anomalies in high-risk patients, and magnetic resonance imaging and endoscopic examinations for suspected complex malformations or diagnostic difficulties.
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Uterine septae
Uterine septae were the commonest congenital abnormalities identified in ~5% of RM women in one series. 28 Since the change from abdominal to hysteroscopic surgical approaches, uterine septae have become amenable to low-risk surgical correction In their recent guidelines for managing uterine septae, the ASRM recommended that 'it is reasonable to consider septum incision', 31 a view supported by the DGGG/OEGGG/SGGG. 7 Until gold-standard RCT-quality evidence emerges, the growing consensus supports septal resection.
Fibroids and other acquired structural defects
An earlier systematic review found an association between fibroids and higher miscarriage rates 36 39 However, in the absence of a matched no-treatment group with submucous fibroids, and given the good pregnancy prospects without intervention even after three miscarriages, 5 it is not known whether surgery was responsible for improved outcomes. There is also a lack of evidence regarding management of polyps and intrauterine adhesions in patients with RM. However, since many clinicians elect to remove cavity-distorting lesions on the basis that they could plausibly impair implantation, this is a difficult area in which to conduct RCTs. 8 Until better quality evidence emerges, the ASRM and DGGG/OEGGG/SGGG propose that it is reasonable to undertake surgical correction in cases of uterine cavity defects associated with fibroids, polyps and adhesions.
7,8,37
INHERITED THROMBOPHILIAS
Thrombophilia refers to an increased risk of developing venous thromboembolism (VTE) and can be acquired (eg APS) or inherited. 40 Inherited thrombophilias include factor V Leiden mutation (FVL G1691A), prothrombin gene mutation (PT G20210A), protein C deficiency, protein S deficiency and anti-thrombin deficiency. 40 Earlier associations between inherited thrombophilia and recurrent fetal loss 41 have not been confirmed in subsequent prospective analyses 42, 43 and a very recent review found no evidence that thromboprophylaxis improves pregnancy outcome. 40 Moreover, a meta-analysis of eight trials involving 483 patients with previous late (≥10 weeks) or recurrent early losses found no benefit with LMWH. 44 A Cochrane review of nine studies involving 1228 women with a history of at least two unexplained miscarriages with or without thrombophilia also found no improvements with LDA, LMWH or a combination. 45 The ongoing ALIFE2 (Anticoagulants for Living Fetuses 2) RCT will hopefully clarify guidance on LMWH use with inherited thrombophilia. 46 For the present, it is not recommended that RM patients be routinely screened for thrombophilia unless otherwise indicated due to prior VTE 7, 8, 18, 40 or be given antithrombotic prophylaxis even if a thrombophilic defect is found.
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ENDOCRINE FACTORS: THYROID FUNCTION, PCOS AND PROLACTIN
While miscarriage is increased with overt hypothyroidism, 47 the association between subclinical hypothyroidism (SCH) and pregnancy loss is less clear. SCH refers to elevated thyroid-stimulating hormone (TSH) with normal free thyroxine levels. 48 Using an upper limit of 4-5 mIU/L for TSH, the prevalence of SCH in women of reproductive age is 4-8%. 49 One uncertainty has been whether SCH should be diagnosed in non-pregnant women trying to conceive using a lower threshold of TSH >2.5 mIU/L rather than 4 mIU/L.
There are few studies of thyroid function specifically within RM populations or that have investigated pregnancy outcomes in relation to pre-pregnancy thyroid function. Two studies using a pre-pregnancy TSH threshold of 2.5 mIU/L found no association with increased miscarriage. 50 48 Another uncertainty pertains to the significance of thyroid autoimmunity (antibodies to thyroid peroxidase (TPO) and/or thyroglobulin (Tg)), which is present in ~14% of reproductively aged women 57 and has been associated with increased miscarriage risk. 58, 59 In one study, the prevalence of TPO-Ab positivity with unexplained RM was similar to the general population and treatment of TPO-Ab positive RM patients with thyroxine did not improve outcomes. 60 However, notably miscarriage risk may be exacerbated when thyroid autoimmunity co-exists with SCH. 61 Consequently, the American Thyroid Association give a strong recommendation for thyroxine use with combined autoimmunity and TSH >4 mIU/L and a weak recommendation to consider thyroxine with autoimmunity and TSH >2.5 mIU/L. 48, 49 Although polycystic ovarian syndrome (PCOS) has been associated with increased miscarriage risk, perhaps related to hyperinsulinaemia and hyperandrogenaemia, there is a lack of clear evidence that PCOS predisposes to RM. 62 Furthermore, a metaanalysis found that metformin, an insulin-sensitising drug often used in PCOS patients, did not reduce miscarriage in PCOS. 63 A single small RCT of 46 patients considered of low quality 64 found that bromocriptine treatment in RM patients with hyperprolactinaemia significantly reduced miscarriage rates. 65 Larger trials are required to clarify the potential benefit of dopamine agonists in RM patients with idiopathic hyperprolactinaemia.
IMMUNOLOGICAL FACTORS AND PROGESTERONE SUPPLEMENTATION
In over half of RM couples, all tests on the parents are normal. 3 In a recent prospective study, no abnormalities were identified in 55% of couples after strict application of the ASRM guidelines. 
Glucocorticoids, IVIg, lymphocyte immunotherapy, aspirin and heparin
Glucocorticoid treatment has produced inconsistent results in RM patients and can increase the risk of prematurity, orofacial clefts, gestational diabetes and hypertension. 7, 66 A recent meta-analysis using strict criteria for defining unexplained RM found no RCTs involving prednisolone. 67 Two recent meta-analyses of intravenous immunoglobulin (IVIg) use in RM found no evidence of improved live birth rates. 67, 68 Recent meta-analyses of allogenic lymphocyte immunotherapy (eg paternal lymphocyte infusion) reported improved live birth rates in the treatment arm. 69, 70 However, these studies have been criticised for their low quality, low numbers of patients and lack of consistency in the patient populations recruited. 67 Finally, the available evidence from RCTs does not support the use of heparin and LDA, either alone or in combination. 45, [71] [72] [73] [74] It should also be noted that transfusion of blood products is not without potentially serious complications and that long-term heparin use risks maternal osteopenia.
Intralipid, TNF-α inhibitors and G-CSF
Intralipid is a fat emulsion used for parenteral nutrition. It has been proposed that intralipid might benefit RM by reducing peripheral blood natural killer (NK) cell activity and suppressing pro-inflammatory cytokines. 75 Intralipid has been evaluated in only one RCT that tested whether a 250 mL infusion on the day of oocyte retrieval (with further infusions if there was a positive pregnancy test) could increase chemical pregnancy rates in RM patients with elevated peripheral blood NK cells (>12%) undergoing IVF. 76 No benefit was found for the primary outcome, chemical pregnancy, although increased rates of ongoing pregnancies and live birth rates were observed, the significance of which requires further investigation by appropriately powered studies.
Tumour necrosis factor (TNF)-α is a proinflammatory cytokine produced by T-helper 1 cells and can be neutralised using anti-TNF-α drugs such as adalimumab (Humira ® ). One small retrospective study found improved live birth rates when anti-TNF-α was combined with other regimes that included heparin, LDA and/or IVIg. 77 However, there are no well-designed prospective studies of anti-TNF-α use in RM patients.
Granulocyte colony-stimulating factor (G-CSF) is a cytokine produced by decidual cells that stimulates granulocyte proliferation and differentiation. One small RCT of 68 women with unexplained RM found that G-CSF treatment (administered subcutaneously from the sixth day after ovulation to the ninth week of gestation) increased live birth rates from 48% in the placebo group to 83% in the treatment group. 78 More recently, a pilot RCT found no benefit following intrauterine G-CSF administration in unexplained RM. A meta-analysis of 10 RCTs (including the PROMISE trial) involving 1586 women with idiopathic RM evaluated the effects of natural and synthetic progesterones administered during the first trimester and commenced after pregnancy confirmation. 82 Lower miscarriage and higher live birth rates were found in the eight studies that used synthetic progesterones. 82 However, included studies spanned more than 60 years, and multiple formulations, dosages and administration routes were used making it difficult to recommend any particular regime. 82 Collectively, these data suggest that progesterone is likely beneficial in unexplained RM. Synthetic progesterone may be superior to natural progesterone, at least when progesterone is commenced after a positive pregnancy test. However, formulation, dosage and route of administration need to be defined.
Natural progesterone may be beneficial but should be started in the luteal phase with consideration given to continuing beyond the first trimester.
OTHER FACTORS: TLC, INFECTION, LIFESTYLE AND SPERM DNA DAMAGE
It is widely accepted that psychological support in a dedicated RM clinic setting complemented with weekly ultrasound scanning (so-called TLC (tender-loving care)) is beneficial. 
CONCLUSION
Recurrent miscarriage is a complex condition requiring consideration of multiple factors for appropriate workup and management ( Table 3 ). The decision to intervene depends on the benefit-to-risk ratio of proposed treatment. APS, uterine structural defects and structural chromosomal abnormalities are the parental pathologies most strongly tied to RM. The benefit of combined unfractionated heparin and LDA in APS is supported by robust prospective evidence. However, further investigation of LMWH efficacy and treatment for non-criteria APS are required. Septal resection is not risk-free but in trained hands, is low-risk. The available evidence supports surgical correction of the septum but is limited to retrospective studies and therefore subject to bias. Similar considerations apply to other uterine cavity defects, fibroids, polyps and adhesions. After appraising the evidence, the ASRM concluded that it is reasonable to consider surgical correction for septae and cavity-distorting fibroids. 31, 37 It is recommended that thyroxine be used for TSH >4 mIU/L. If thyroid autoimmunity co-exists, when thyroxine may be considered at TSH >2.5 mIU/L. Thrombophilia screening is no longer recommended. 
